Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy

Supportive Care in Cancer

Volumn 22, Issue 8, 2014, Pages 2039-2048

  Yoon, Young Kyung ^a   Kim, Min Ja ^a   Sohn, Jang Wook ^a   Kim, Hye Suk ^a   Choi, Yoon Ji ^a   Kim, Jung Sun ^a   Kim, Seung Tae ^a   Park, Kyong Hwa ^a   Kim, Seok Jin ^b   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Park, Yong ^a  

^a Korea University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Clostridium difficile; Malignancy; Neutropenia; Treatment outcome

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GLUCOCORTICOID; METHOTREXATE; METRONIDAZOLE; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTE COUNT; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; TEACHING HOSPITAL; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HOSPITALS, TEACHING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84905119616     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2174-7     Document Type: Article

References (36)

1. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs andmortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34(3):346-353 (Pubitemid 34062235)
2. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM (2008) Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 29(9):823-828
3. Bishop KD, Castillo JJ (2012) Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53(8):1617-1619
4. Gifford AH, Kirkland KB (2006) Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 25(12):751-755 (Pubitemid 44786650)
5. Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S (2013) Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol 34(2):127-132
6. Rampling A, Warren RE, Bevan PC, Hoggarth CE, Swirsky D, Hayhoe FG (1985) Clostridium difficile in haematological malignancy. J Clin Pathol 38(4):445-451 (Pubitemid 15106610)
7. Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16(8):1566-1572
8. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, Marr KA (2012) Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 54(8):1053-1063
9. Schwaber MJ, Simhon A, Block C, Roval V, Ferderber N, Shapiro M (2000) Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 19(1):9-15 (Pubitemid 30093375)
10. Kyne L, Sougioultzis S, McFarland LV, Kelly CP (2002) Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 23(11):653-659 (Pubitemid 35315987)
11. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN (1992) Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166(3):561-567
12. Dial S, Delaney JA, Barkun AN, Suissa S (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294(23):2989-2995 (Pubitemid 41817660)
13. McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320(4):204-210 (Pubitemid 19034145)
14. Johnson S, Gerding DN (1998) Clostridium difficile - associated diarrhea. Clin Infect Dis 26(5):1027-1034, quiz 1035-1036
15. Dettenkofer M, Ebner W, Bertz H, Babikir R, Finke J, Frank U, Rüden H, Daschner FD (2003) Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant 31(9):795-801 (Pubitemid 36656672)
16. Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG (2001) Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33(6):786-791 (Pubitemid 32831834)
17. Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 71(1):104-107 (Pubitemid 28492402)
18. Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8(10):1113-1119
19. Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61(3):369-372 (Pubitemid 26169263)
20. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431-455
21. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45(3):302-307 (Pubitemid 47101025)
22. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S (2007) Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 55(6):495-501 (Pubitemid 350082477)
23. Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM (2008) Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 143(5):623-629
24. Pant C, Sferra TJ, Bass PF, Burton GV, Minocha A (2010) Letter in response to the article "Optimum timing of blood tests formonitoring patients with Clostridium difficile-associated diarrhea" (J Investig Med. 2010;58[4]:621-624). J Investig Med 58(6):807
25. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364(5):422-431
26. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6(2):122-174 (Pubitemid 351340523)
27. Bauer MP, Kuijper EJ, van Dissel JT (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 15(12):1067-1079
28. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245-1251 (Pubitemid 24361532)
29. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471-1474
30. Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I (2011) Infection probability score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs 15(5):404-409
31. Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M (2013) A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. doi:10.1177/1078155213490004
32. Chakrabarti S, Lees A, Jones SG, Milligan DW (2000) Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 26(8):871-876
33. Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61(1):1-8
34. Bloomfield MG, Sherwin JC, Gkrania-Klotsas E (2012) Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 82(1):1-12
35. Bartlett JG (2008) The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 46(10):1489-1492
36. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171(5):466-472 (Pubitemid 39179608)